1. Age 18 to 60 years
2. Acute myeloid leukemia (AML) in first or second complete remission. Complete remission (CR) must have been achieved after no more than 2 cycles of induction/re-induction chemotherapy. Patients in first CR may have received no more than 1 cycle of consolidation therapy. Patients in second CR should proceed to transplant without further consolidation. No more than 6 months can have elapsed from CR to transplant
3. Must not have M3-AML in first CR, acute leukemia following blast transformation of prior chronic myelogenous leukemia or other myeloproliferative disease, AML with t(8:21) in first CR, M4Eo-AML with inv 16 in first CR, diagnosis of myelodysplastic syndrome for more than 3 months prior to diagnosis of AML or patients with treatment-related AML
4. Must not have had a prior transplant
5. Must not have an allergy to iron dextran or murine proteins
6. Patients must have a 6/6 HLA antigen (A, B, DRB1)-compatible sibling donor for entry on this protocol
7. Karnofsky performance status > 70%
8. Patients must have normal heart, lung, liver and kidney function

This study will examine the outcome of the nonmyeloablative transplant regimen with respect to side effects, safety, engraftment (the body’s acceptance of the transplanted cells), and overall and disease-free survival compared to the standard transplant approach. The study involves a combination of treatments. The preparative regimen is the experimental part of the bone marrow transplant (and this study) and consists of:

• Photopheresis, a form of therapy in which UVADEX (brand name of the drug liquid methoxsalen) is injected into the blood, exposing the blood cells to ultraviolet light; 

• Chemotherapy, whereby Pentostatin (a drug) is injected to target a type of white blood cell (a T-cell) that is involved in transplant acceptance or rejection; and 

• Total Body Irradiation 

1. Have either non-Hodgkin’s lymphoma or Hodgkin’s disease that has relapsed following a course of high dose chemotherapy and autologous stem cell transplantation OR have failed to mobilize adequate stem cells to undergo autologous stem cell transplant;
2. Be greater than or equal to 90 days from prior transplant; 
3. Be matched to a compatible donor;
4. Be 18 years of age or older;
5. Have at least one measurable or evaluable (able to be evaluated) disease parameter;
6. Not be HIV positive;
7. Meet minimum requirements for adequate performance status; and lung, heart, kidney, and liver function; and

This research study is being conducted with patients who have a new diagnosis of graft-versus-host disease (GVHD) after receiving an allogeneic (donor -- the person who gave the stem cells for the transplant) stem cell transplant. Sometimes, GVHD can be controlled with treatments that use corticosteroids (like prednisone). More often, patients need long-term drug therapy to control their GVHD symptoms and to suppress the immune system. Because of the risks of continued GVHD, four new drugs to control GVHD are being tested in this study:

1. Etanercept (also known as Enbrel)

2. Mycophenolate Mofetil (MMF) (also known as Cellcept)

3. Denileukin Diftitox (also known as Ontak)

4. Pentostatin (also known as Nipent)
   
   All patients in the study will be randomly assigned to receive one of the four new study drugs. 

1. Have had a prior allogenic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative transplants are also eligible;
2. Be acute GVHD requiring systemic therapy within 24 hours of diagnosis;
3. Be 10 years of age or older;
4. Meet minimum requirements for clinical status and organ function; 

This study is intended to determine whether the combination of AMD3100 with G-CSF is better than G-CSF alone in making more stem cells available for transplant to patients being treated for non-Hodgkin’s lymphoma. 
Patients choosing to participate in the study will receive the standard treatment for collecting stem cells which consists of daily injections of G-CSF each morning for four days in a row. On the 4th day, patients will receive either normal saline (placebo) or the study drug AMD3100 given as a subcutaneous (under the skin) injection. Patients will then return to the clinic the following morning to have the 5th morning dose of G-CSF. At that time stem cells will be collected, and, if enough are collected then, the experimental portion of the study will end and the patient will proceed with the routine transplant. If enough stem cells cannot be collected following the fifth morning dose of G-CSF (the first day of collection), the patient will continue receiving G-CSF in the morning and AMD3100 or placebo in the evening. This procedure will continue until the required amount of stem cells is collected, for a maximum of 4 collections. If the patient fails to collect an adequate number of cells, the treatment on this protocol will be stopped but the patient will have the option to go into another treatment in this protocol with G-CSF and AMD3100. The investigating doctor will discuss treatment options available to those who repeat the mobilization phase.

1. A biopsy-confirmed diagnosis of NHL (all types excluding chronic lymphocytic leukemia)
2. Eligible for autologous transplantation
3. In first or second complete remission or partial remission
4. Not received their last cycle of chemotherapy within the preceding four-week period (Rituxan® is not considered chemotherapy for the purpose of this study) 
5. An ECOG performance scale of 0 or 1 
6. Recovered from all acute toxic effects of prior chemotherapy
7. Adequate bone marrow, liver, kidney, heart and lung function

1. Patients scheduled to undergo HLA-identical sibling donor allogeneic hematopoietic stem cell transplantation for any indication, malignant or non-malignant.
2. Patients may be enrolled on institutional allogeneic stem cell transplant protocols using both ablative and non-myeloablative preparative regimens.
3. Patients may not be enrolled on institutional allogeneic stem cell transplant protocols investigating GVHD prophylaxis or treatment.
4. Patients who develop acute GVHD of clinical grade II-IV that requires systemic immunosuppressive therapy with systemic corticosteroids with concurrent Cyclosporine or FK506 are eligible.
5. Patients who develop de novo extensive chronic GVHD that requires systemic immunosuppressive therapy that includes systemic corticosteroids are eligible.
6. Patients with evidence of relapsed or progressive malignant disease at the time of GVHD are not eligible.

1. Patients must have one of the following hematologic malignancies: AML, ALL, CML, Myelodysplastic syndrome, or Myeloproliferative disease.
2. Patients with prior allogeneic or autologous transplants using any hematopoietic stem cell source are not eligible.
3. Patients must have normal lung function.
4. Patients must have normal liver and kidney function.

1. Patients must have symptomatic stage II or III multiple myeloma requiring treatment.
2. Patients 70 years of age or younger are eligible.
3. Patients must have received at least three months of initial systemic therapy and be within 3 to 9 months of initiation of that therapy (this time frame excludes the time for mobilization chemotherapy).
4. Patients must have adequate cardiac, liver, kidney and lung function.
5. Patients must not have received prior allogeneic or autologous peripheral stem cell transplant.

1. Recurrent hematologic malignancies or sever aplastic anemia
2. No available HLA-matched sibling
3. Cannot receive myeloablative conditioning regimens due to advanced age and/or co-morbid conditions
4. Karnofsky Performance Status >70% for adults and >50% for <16 years
5. Adequate organ function 
6. HIV Negative
7. No acute leukemia in refractory relapse or primary myelofibrosis
8. No active central nervous system leukemia

1. Histologic confirmation of AML, high risk ALL, CML, myelodysplastic syndromes, lymphoma (intermediate or high grade)
2. 55 years old or younger
3. ECOG performance status of 2 or less
4. No evidence of active infection; HIV negative
5. No significant cardiac or renal disease
6. Adequate pulmonary and liver function
7. No stem cell transplant during the previous year

1. No evidence of central nervous system involvement
2. No prior chemotherapy for lymphoma except for a single course of CHOP chemotherapy
3. No prior radiation therapy
4. Over 15 years of age but not have reached the 66th birthday
5. Good general medical condition
6. No significant coronary artery disease, cardiomyopathy, congestive heart failure or dysrhythmia

1. Previously untreated for malignancy
2. Age 15-60 years old
3. No intercurrent organ damage, psychiatric disorder, drug abuse, or pregnancy
4. Must be HIV negative
5. Performance status of 0 or 1
6. Central nervous system negative for leukemia
7. No significant cardiac disease

1. Patients with ANLL after induction failure, or in first complete remission with high risk features including stem cell or biphenotypic classification (AML-M0), erthroleukemia (AML-M6), acute megakaryocytic leukemia (AML-M7), cytogenetic markers indicative of poor prognosis, or failure to achieve complete remission after standard induction therapy.
2. All patients with ALL or ANLL in second or subsequent remission.
3. All patients with CML in chronic phase. CML patients with accelerated phase or blast crisis are eligible after reinduction chemotherapy places them in chronic phase.
4. Patients with high risk ALL in first complete remission, with high risk being defined by the presence of t(4;11), t(9;22), or t(8:14) translocation, or patients presenting with extreme hyperleukocytosis (initial WBC >500K/ml) or failure to achieve complete remission after standard induction therapy.
5. Patients with myelodysplastic syndrome with evidence of evolution to AML, e.g., refractory anemia with excess blast (RAEB) or refractory anemia with excess blasts in transformation (RAEB-t).
6. All patients with non-Hodgkin's lymphoma, ANLL or ALL with recurrent disease after autologous stem cell transplantation.

The Umbilical Cord Blood Registry will be searched to locate a suitable donor. Patients will be accepted as umbilical cord blood transplant candidates if they meet all of the following conditions:

1. They do not have an HLA-ABC/DR identical related bone marrow or umbilical cord blood donor.
2. They do not have a 5/6 antigen matched related bone marrow or umbilical cord blood donor.
3. Their condition precludes waiting to search and find a donor in the National Marrow Donor Registry.

This study will compare disease-free survival (DFS) between two consolidation regimens: Gemtuzumab-ozogamicin followed by autologous peripheral blood stem cell (PBSC) transplant or directly to autologous transplant.  Patients will be randomized to one of two induction therapy arms.  Patients randomized to Arm A will receive Daunorubicin by IV injection over 10-15 minutes on days 1,2 and 3 and cytarabine by continuous IV infusion on days 1 through 7.  Patients randomized to Arm B will receive high-dose daunorubicin by IV infusion over 10-15 minutes on days 1,2 and 3 and cytarabine by continuous IV infusion on days 1 through 7.  All patients will receive up to 2 cycles of induction therapy in the attempt to gain a complete remission.  Patients with appropriate donors who are considered poor risk for transplant will be allocated to allogeneic transplant.  Patients who do not meet the eligibility criteria for allogeneic transplant will be randomized to consolidation therapy and autologous transplant. 

1. Patients must have acute myeloid leukemia (AML) with evidence of CD33 positivity by flow cytommetry.

2. Patients must not have been previously treated with radiation therapy or cytotoxic chemotherapy.   Previous therapy with corticosteroids or hydroxyurea will not exclude the patient.

3. Patients must have adequate bone marrow, cardiac, hepatic and renal function.

4. Patients must not have had blastic transformation of chromic myelogenous leukemia or secondary AML.  AML, which has evolved within 6 months from myelodysplastic syndrome (MDS), will be allowed.

5. Patients must attain a complete remission after up to two cycles of induction therapy to continue protocol treatment.